| Field | Specification |
|---|---|
| Alternative names | LV-CMV-Gluc-Puro | LV-CMV-hGluc-Puro | LV-CMV-Gluc-IRES-Puro | LV-CMV-hGluc-IRES-Puro | CMV-hGluc-Puro Lentivirus |
| Applications | |
| Purity | |
| Titer | |
| Promoter | |
| Reporter/Tag | |
| Expression regulation | |
| Selection marker | Puromycin |
| Biosafety level | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Vector Overview
LV-CMV-hGluc-Puro is a pre-made lentivirus which over-expresses codon-optimized/humanized Gaussia luciferase (hGluc) under CMV promoter with co-expression of puromycin selection in an IRES cassette. The humanized form of Gaussia luciferase (hGLuc) was confirmed to be nontoxic and naturally secreted after overexpression in mammalian cells. hGLuc generated over 1000-fold higher bioluminescent signal intensity from live cells and over 100-fold higher intensity from viable cells alone (not including secreted luciferase) or cell lysates, compared to humanized forms of firefly (hFLuc) and Renilla (hRLuc) luciferases expressed under similar conditions. Furthermore, hGLuc showed 200-fold higher signal intensity than hRLuc and intensity comparable to that of hFLuc in vivo under standard imaging conditions. Gaussia luciferase provides a sensitive means of imaging gene delivery and other events in living cells in both tissue culture and in vivo, with a unique combination of features including high signal intensity, secretion, and ATP independence, thus being able to report from the cells and their environment in real time. Ready to use format.
Technical Details
| Catalog No. | SL100314 |
|---|---|
| Promoter | CMV |
| Reporter / Tag | Gaussia Luciferase (hGluc) |
| Expression Regulation | Constitutive |
| Selection Marker | Puromycin |
| Titer | >1E+9 TU/mL |
| Storage Buffer | PBS |
| Purity / Grade | In vivo grade and OK for both in vitro tissue culture infection and in vivo injection * Concentrated via PEG precipitation followed by ultra-centrifugation at 25000 rpm |
| Biosafety Level | BSL-2 |
| Sizes | 25 uL; 25 uL x 2 |
Applications
- Lentiviral Transduction: stable delivery of the cassette into dividing and non-dividing cells for long-term expression.
Biosafety
LV-CMV-Gluc-Puro is a pre-packaged lentiviral vector classified as BSL-2. Handle in a certified biosafety cabinet under institutional BSL-2 practices, decontaminate all contact surfaces and waste, and follow local regulations for viral vector work.
Safety & Handling
Store at -80°C; avoid repeated freeze-thaw cycles. Ships on dry ice. Supplied in PBS. For research use only; not for diagnostic or therapeutic use.
Can't find the lentiviral construct you need, or want to adjust key design elements? Contact us to discuss custom LV design and optional add-ons.
Common customization requests
- Insert / payload: replace the gene/sequence, swap to a different isoform, add mutations, or optimize cloning features.
- Expression design: change promoter (e.g., CMV/EF1α/PGK), add enhancers, or adjust regulatory elements.
- Reporters: add/swap GFP/RFP/mCherry/luciferase (single or dual reporters where applicable).
- Selection markers: add/swap puromycin/blasticidin/neomycin or fluorescent selection options.
- Vector format: switch between OE, shRNA, CRISPR (sgRNA/Cas systems), or control vectors (where supported).
Add-ons you can request
- Control viruses: empty vector, non-targeting shRNA, reporter-only controls, or matched backbone controls.
- Packaging / format: concentration options, aliquoting, or custom fill volume for screening workflows.
- Documentation: construct map/sequence confirmation package (as available) and batch documentation.
What to include in your request
- Target cell type/model (cell line or primary cells) and intended readout (reporter, knockdown, OE, etc.)
- Insert sequence (FASTA) or reference ID, plus any required tags/mutations
- Promoter, reporter, and selection marker preferences
- Desired scale and preferred format (aliquots / concentration requests)
Email us at support@biohippo.com or use the Talk to a Scientist request form.
Liang P, Henning SM, Grogan T, Elashoff D, Ye H, Cohen P, et al. (2022) Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation-dependence on GPR120. Prostate Cancer Prostatic Dis, 25(3), 539-546. 10.1038/s41391-021-00440-2